FDA panel backs lower dose of Lilly-Incyte arthritis drug over higher
(Reuters) - A rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp should not be approved at a higher dose, a U.S. Food and Drug Administration advisory committee voted on Monday, while backing the approval of a lower dose.
from Reuters: Health News https://reut.rs/2Jlq185
http://bit.ly/2zwRqiM